Affinity Asset Advisors’s Climb Bio CLYM Stock Holding History

Affinity Asset Advisors’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.7M	Buy	972,000 +272,000	+39%	+$2.81M	0.57%	51
2026 Q1	$4.79M	Sell	700,000 -600,000	-46%	-$3.46M	0.25%	70
2025 Q4	$5.2M	Hold	1,300,000	–	–	0.3%	64
2025 Q3	$2.61M	Sell	1,300,000 -200,000	-13%	-$371K	0.23%	69
2025 Q2	$1.86M	Hold	1,500,000	–	–	0.25%	59
2025 Q1	$1.83M	Buy	1,500,000 +1,000,000	+200%	+$1.62M	0.17%	69
2024 Q4	$900K	Sell	500,000 -1,000,000	-67%	-$3.62M	0.12%	71
2024 Q3	$7.63M	Sell	1,500,000 -170,661	-10%	-$1.21M	1.04%	32
2024 Q2	$11.9M	Buy	+1,670,661	New	+$11.1M	1.37%	22

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Affinity Asset Advisors's CLYM Position: Q2 2026 in Review

Affinity Asset Advisors increased its Climb Bio (CLYM) stake by 39% in Q2 2026, buying an estimated $2.81M and bringing the position to 972,000 shares worth $12.7M. The position accounts for 0.57% of the portfolio, ranked #51.

Affinity Asset Advisors first reported a position in CLYM in Q2 2024 and has held it in 9 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

Affinity Asset Advisors held 972,000 shares of Climb Bio worth $12.7M as of Q2 2026.
Affinity Asset Advisors bought 272,000 Climb Bio shares in Q2 2026, an estimated $2.81M.
Climb Bio made up 0.57% of Affinity Asset Advisors's portfolio in Q2 2026, its #51 holding.
Affinity Asset Advisors first reported a position in Climb Bio in Q2 2024 and has held it in 9 quarters since.
109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.